Immunotherapy Advances Offer Hope for People with HIV and Cancer

New research is bolstering evidence that immune checkpoint inhibitors (ICIs) are both safe and effective for individuals living with HIV who also have cancer. A growing body of research suggests immunotherapy may play a role in achieving a functional cure for HIV itself.

Understanding Immune Checkpoint Inhibitors

Immune checkpoint inhibitors represent a significant breakthrough in cancer treatment. These monoclonal antibodies work by interfering with receptors on immune cells that regulate the immune response. For example, drugs like Keytruda (pembrolizumab) block PD-1 or its ligand, PD-L1, restoring T-cell activity. Yervoy (ipilimumab) blocks CTLA-4, promoting T-cell multiplication [1].

Addressing Historical Concerns

Historically, there was reluctance to use ICIs in people with HIV due to concerns that the virus’s weakening of the immune system – specifically the depletion of CD4 T cells – might diminish the effectiveness of immunotherapy. Early clinical trials often excluded individuals with HIV because of uncertainty regarding potential adverse reactions or interactions with antiretroviral medications [1].

Recent Research and the CATCH-IT Consortium

Recent studies, including those conducted through the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium, are changing this landscape. The CATCH-IT Consortium, established in 2021, has been exploring ICI use in patients with both cancer and HIV from seven countries [1]. These studies indicate that ICIs are as effective and safe in people with HIV as in those without the virus.

Managing Cancer in People with HIV: A Complex Approach

Treating cancer in individuals with HIV requires a comprehensive and multidisciplinary approach. Healthcare teams must consider potential drug-drug interactions, manage opportunistic infections, and address the possibility of multiple cancer diagnoses occurring simultaneously [1].

Immunotherapy and the Potential for an HIV Functional Cure

Beyond cancer treatment, immunotherapy is being investigated for its potential role in achieving a functional cure for HIV. Research focuses on augmenting both antitumor and antiviral cellular immune responses [3].

The Evolving Landscape of HIV and Cancer Treatment

Although antiretroviral therapy (ART) has significantly reduced AIDS-related mortality and the incidence of AIDS-defining cancers, there has been a rise in Non-AIDS-defining cancers (NADCs) among people living with HIV [3]. New ART drugs, such as Ibalizumab and Pro 140, are also contributing to the evolving landscape of HIV management [3]. Combinations of ART, immunotherapy, and cancer immunotherapy drugs hold promise for treating malignancies in people living with HIV [3].

Key Takeaways

• Immune checkpoint inhibitors are proving to be a safe and effective cancer treatment option for people living with HIV.
• Research suggests immunotherapy may contribute to a functional cure for HIV.
• Managing cancer in people with HIV requires a multidisciplinary approach considering drug interactions and opportunistic infections.
• New ART drugs and combined treatment strategies are emerging as promising avenues for improved care.